Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

VistaGen and Cato BioVentures sign strategic agreement for CNS products

March 24, 2006

Orphan drug designation for HD-02 for Huntington's disease

March 24, 2006

Second phase III study begins for Viprinex in acute ischemic stroke

March 24, 2006

FDA extends review period for Tysabri in MS

March 23, 2006

Samaritan's Alzheimer's adult stem cell drug progresses through preclinical testing

March 23, 2006

Asthma therapy efficacious in ALS

March 23, 2006

Aquavan begins pivotal phase III program

March 23, 2006

Neuromed and Merck collaborate on novel N-type calcium channel compounds

March 23, 2006

Recent patents cover novel compounds for Alzheimer's and other neurological disorders

March 22, 2006

Elan completes sale of European Prialt rights to Eisai

March 22, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...